News
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted canc ...
Barclays (LON: BARC) has initiated coverage on Galderma Group AG (SIX: GALD) and Zealand Pharma (NASDAQ: ZEAL) with Overweight ratings, citing distinct growth dri ...
While the broader European market is up mid-single digits year-to-date, the SXDP pharma index has underperformed, losing more ...
For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...
"Rising liver disease cases and biotech innovations are fueling demand for advanced therapies, with personalized medicine and fibrosis-targeting treatments shaping the global market landscape." BOSTON ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF – Research Report) and Alkermes (ALKS – Research Report). Confident I ...
“Steven brings a unique 360-degree perspective on global drug development gained from a career at major pharma companies, CROs and the FDA,” said Adam Steensberg, Chief Executive Officer, Zealand ...
Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or ...
Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or ...
Zealand Pharma is optimistic about its future, expecting the closure of the Roche deal in Q2 2025. Analysts share this optimism, with a strong buy consensus and price targets ranging from $110 to ...
Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results